Learn from these Leaders: |
 |
Farah Jivraj
Director, Market Access
Janssen-Ortho & Ortho
Biotech |
 |
Wayne Critchley
Senior Advisor
Canadian Agency for Drugs and
Technologies in Health |
 |
Barbara Ouellet
Executive Director
Patented Medicine Prices Review Board |
 |
Philip Schwab
Vice President, Industry Relations
BIOTECanada |
 |
Vic Medland
President, Group Insurance Services
Ontario Teachers Insurance Plan |
 |
Dr. Philip A. Baer, MDCM, FRCPC, FACR, Chair, Section of Rheumatology,
Ontario Medical Association |
|
| |
Conference Agenda At - A - Glance |
 |
| |
| 7:30 AM Registration and Continental Breakfast |
| |
| 8:15 AM Opening Comments from the Chair |
 |
| Wayne Critchley, Senior Advisor, CADTH |
|
| |
8:30 AM The Patented Medicine Prices Review Board (PMPRB)
Understanding the impact of the new Excessive Price Guidelines |
|
| Barbara Ouellet, Executive Director, Patented Medicine Prices Review Board |
|
| |
9:15 AM Private payer panel
Assessing the current and future challenges for biologics within a private payer context |
|
| Vic Medland, President, Group Insurance Services, Ontario Teachers Insurance Plan |
| Scott Warner, Director of Underwriting, D and R Insurance Administrators |
| Suzanne Lepage, Co-Chair, Group Insurance and Pharmaceutical Committee (GIPC) |
Kevin West, (Moderator), Vice President, Operations, Specialty Services, Innomar Strategies Inc.
|
 More to come...
|
|
| |
| 10:00 AM Networking Break |
| Interact with conference speakers and fellow attendees. |
| |
10:30 AM Canadian Agency for Drugs and Technologies in Health (CADTH)
The role of CADTH in Canada’s health care system |
|
| Wayne Critchley, Senior Advisor, CADTH |
|
| |
11:15 AM Bill C-51 Update: Progressive Licensing
Assessing biologics on a risk-benefit-based approach to improve treatment |
|
| Joanne Garrah, Program Officer, Office of Legislative and Regulatory Policy, Planning and International Affairs, Directorate of Health Canada |
|
| |
| 12:00 PM Networking Luncheon |
| Join the conference speakers and your peers for a relaxing luncheon. |
| |
1:30 PM Case Study: Stelara
Patient outcome and quality of life improvements through biologics |
|
| Farah Jivraj, Director, Market Access, Janssen-Ortho & Ortho
Biotech |
|
| |
2:15 PM Planning the Launch of a Biologic
Specific considerations for launching new biologics into the Canadian market |
|
| Kevin West, Vice President, Operations, Specialty Services, Innomar Strategies Inc. |
|
| |
| 3:00 PM Networking Break |
| Interact with conference speakers and fellow attendees. |
| |
3:30 PM Patient’s Perspective
How access and education improves patient outcomes: Understanding biologics from the patient’s perspective |
|
| George Tolomiczenko, Executive Director of the CCFC Inflammatory Bowel Disease Research Institute and Scientific Liaison, Crohn’s and Colitis Foundation of Canada |
| Christine Jackson, Executive Director, Canadian Skin Patient Alliance |
| More to come... |
|
| |
| 4:15 PM Conference Adjourns to Day Two |
| |
5:00 PM Social Activities...
A number of social activities will be arranged for the evening of day one -bring our business cards and interact with your peers!**
|
| |
| |
 |
| |
| 8:00 AM Registration & Continental Breakfast |
| |
| 8:45 AM Opening Remarks from the Chair |
| Denis Morrice, Executive Director, Ontario Rheumatology Association |
|
| |
9:00 AM Update: State of the Industry
Gain a better understanding of the biologics environment to better prepare for the years ahead |
|
| Philip Schwab, Vice President, Industry Relations, BioTech Canada |
|
| |
9:45 AM Subsequent Entry Biologics Panel
What Health Canada’s recent guidelines surrounding Subsequent Entry Biologics and means for the industry: Comparability and other regulatory factors |
|
| Karen Burke, Director of Regulatory Affairs, Amgen |
| Philip Schwab, Vice President, Industry Relations, BioTech Canada |
| Patrick Bedford, Sr. Policy Analyst, Health Canada |
| More to come... |
|
| |
| 10:45 AM Networking Break |
| Interact with conference speakers and fellow attendees. |
| |
| 11:15 AM Addressing patient needs to facilitate superior patient outcomes |
|
| Martin Esterhammer, President, Shoppers Drug Mart Specialty Health Network |
|
| |
| 12:00 PM Networking Luncheon |
| Join the conference speakers and your peers for a relaxing luncheon. |
| |
| 1:30 PM Pharmacovigilance: Monitoring biologics to ensure continued safety and limit adverse effects |
|
| Andrew Erdman, MD, Sr. Drug Safety Scientist, Genentech |
|
| |
| 2:15 PM Understanding The Physician’s Perspective In Facilitating And Improving Outcomes |
|
| Dr. Philip A. Baer, MDCM, FRCPC, FACR, Chair, Section of Rheumatology, Ontario Medical Association |
|
| |
| 3:00 PM Networking Break |
| Interact with conference speakers and fellow attendees. |
| |
3:30 PM Legal Update
Biologics, intellectual property law, and the future challenges for the pharmaceutical and biotechnology industry |
|
| Lesley Rapaport, Associate Chair, Vancouver Biotechnology Practice Group, Borden Ladner Gervais |
|
| |
| 4:15 PM Meeting the challenges of cost reimbursement to meet patient needs better |
|
| George Wyatt, Managing Director, Wyatt Health Management |
|
| |
| 5:00 PM Conference Adjourns |
|
Maximize Reimbursement 
